Moreover, in vitro and in vivo studies showed that PTGDS inhibition distinctly inhibited DLBCL progression through MYH9-mediated regulation of Wnt–β-catenin–STAT3 signaling. This evidence concerns the gene MYH9 and diffuse large B-cell lymphoma.